stoxline Quote Chart Rank Option Currency Glossary
RedHill Biopharma Ltd. (RDHL)
1.66  -0.34 (-17%)    12-01 16:00
Open: 1.89
High: 1.89
Volume: 8,168,906
Pre. Close: 2
Low: 1.58
Market Cap: 18(M)
Technical analysis
2023-12-01 4:22:19 PM
Short term     
Mid term     
Targets 6-month :  2.5 1-year :  3.83
Resists First :  2.14 Second :  3.27
Pivot price 0.87
Supports First :  0.3 Second :  0.25
MAs MA(5) :  1.96 MA(20) :  0.73
MA(100) :  0.82 MA(250) :  3.37
MACD MACD :  0.3 Signal :  0.1
%K %D K(14,3) :  63 D(3) :  73.4
RSI RSI(14): 62.3
52-week High :  11.52 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RDHL ] has closed below upper band by 26.9%. Bollinger Bands are 485% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.89 - 1.9 1.9 - 1.91
Low: 1.56 - 1.57 1.57 - 1.58
Close: 1.64 - 1.66 1.66 - 1.67
Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Headline News

Thu, 30 Nov 2023
Healthcare Stocks Moving Thursday: SNGX, NBSE, IMGN, AMPE, VVOS, RDHL, MOTS, ARWR - InvestorsObserver

Thu, 30 Nov 2023
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today? - InvestorPlace

Thu, 30 Nov 2023
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are ... - UK

Thu, 30 Nov 2023
Premarket Mover: RedHill Biopharma Ltd (RDHL) Down 21.53% - InvestorsObserver

Wed, 29 Nov 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Tue, 28 Nov 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 11 (M)
Shares Float 1,110 (M)
Held by Insiders 4.3 (%)
Held by Institutions 11.1 (%)
Shares Short 294 (K)
Shares Short P.Month 17 (K)
Stock Financials
EPS -8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.09
Profit Margin 32.3 %
Operating Margin -245.5 %
Return on Assets (ttm) -17.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -90.2 %
Gross Profit (p.s.) 0
Sales Per Share 3.22
EBITDA (p.s.) -2.18
Qtrly Earnings Growth 0 %
Operating Cash Flow -26 (M)
Levered Free Cash Flow -39 (M)
Stock Valuations
PE Ratio -0.21
PEG Ratio 0
Price to Book value 1.52
Price to Sales 0.51
Price to Cash Flow -0.71
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android